Tilianin inhibits the human ovarian cancer (PA-1) cell proliferation via blocking cell cycle,inducing apoptosis and inhibiting JAK2/STAT3 signaling pathway

Ovarian cancer is one of the deadliest gynecologic malignancies and is the seventh leading cause of mortalities and morbidities globally. Although there are various therapeutic strategies, a major challenge for scientific community is to come up with effective strategy to treat ovarian cancer. Tilianin, a polyphenol flavonoid is well known for its extensive biological actions like cardioprotective, neuroprotective, anti-oxidant, anti-inflammatory, anti-diabetic and anti-tumor properties. The current study is designed to investigate the anti-cancer action of Tilianin in ovarian cancer (PA-1) cells. The findings of this study revealed that Tilianin treatment results in significant and concentration dependent decrease in cell viability. The growth inhibiting action of Tilianin is associated with apoptosis which was confirmed by DAPI and AO/EtBr staining. The Tilianin-triggered apoptosis in PA-1 cells was correlated with elevated generation of ROS, loss of mitochondrial membrane potential, alterations in pro-apoptotic (upregulated mRNA expression of Bax) and anti-apoptotic (downregulated mRNA expression of Bcl2) factors and activation of caspase-8, −9 and −3. Cell cycle analysis revealed that Tilianin treatment prevented G1/S transition through reduced mRNA expression of cyclin D1. Additionally, the findings of this study also showed Tilianin inhibited JAK2/STAT3 signaling (downregulated expression of pJAK2, JAK2, pSTAT3, and STAT3) with no change in mRNA expression level of ERK indicating its non-involvement in the apoptotic and/or growth inhibition of ovarian cancer cells. In conclusion, the findings of this exploration provided clear evidence of anti-cancer effects of Tilianin in PA-1 cells through its anti-proliferative action, ability to induce apoptosis both through extrinsic and intrinsic pathways, cell cycle (G1/S) arrest and JAK2/STAT3 signaling inhibition.     

田蓟苷对高脂饮食小鼠血脂代谢的改善作用及肠道菌群的影响

目的初步探讨田蓟苷改善高脂饮食小鼠血脂代谢的作用机制。方法将60只C57BL/6J小鼠随机分为对照组、高脂饮食组及田蓟苷低、中、高剂量给药组(50、100、200 mg/kg)和阿托伐他汀给药组(10 mg/kg),每组10只,连续给药12周后,检测各组小鼠血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL C)和低密度脂蛋白胆固醇(LDL C)水平。采用Western Blot法检测各组小鼠肝脏组织中SREBP 2和LDLR蛋白表达。通过16S rDNA基因实时荧光定量PCR法检测各组小鼠肠道菌群变化。结果与对照组相比,高脂饮食组小鼠血清TC、TG、HDL C和LDL C水平明显升高(t=-3.966,P=0.001;t=-3.438,P=0.003;t=3.811,P=0.001;t=-6.591,P<0.001),肝脏中SREBP 2和LDLR蛋白表达明显下调(t=7.198,P<0.001;t=8.892,P<0.001)。与高脂饮食组相比,田蓟苷高剂量给药组和阿托伐他汀给药组小鼠血清TC、LDL C水平明显降低(TC:t=2.483,P=0.023;t=3.300,P=0.004。LDL C:t=2.535,P=0.021;t=3.836,P=0.001),肝组织中的SREBP 2和LDLR蛋白水平明显上调(SREBP 2:t=-2.188,P=0.042;t=-3.317,P=0.007。LDLR:t=-2.649,P=0.016;t=-2.249,P=0.037)。与对照组相比,高脂饮食组小鼠肠道中厚壁菌门水平明显升高(t=-2.287,P=0.047),而拟杆菌门、双歧杆菌属、乳杆菌属、嗜黏蛋白阿克曼菌和普拉梭菌水平明显降低(t=3.127,P=0.006;t=2.737,P=0.014;t=3.542,P=0.002;t=3.491,P=0.003;t=2.780,P=0.012)。与高脂饮食组相比,田蓟苷高剂量给药组小鼠肠道中拟杆菌门、乳杆菌属和嗜黏蛋白阿克曼菌水平明显升高(t=-2.613,P=0.020;t=-2.558,P=0.024;t=-2.109,P=0.049)。结论田蓟苷改善高脂饮食诱导的血脂代谢紊乱可能与肝脏中SREBP 2和LDLR蛋白表达及肠道菌群结构变化有关,但其机制仍需进一步研究。